Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Talking ATTD, 780G, Rumors And Missteps With Medtronic’s Diabetes Leaders

Executive Summary

Medtech Insight spoke to the president of Medtronic’s diabetes business, Que Dallara, as well as two of the company’s medical affairs directors, about the company’s recently published data, and the timeline for the US launch of its 780G system.

You may also be interested in...



‘Closest To What The Pancreas Would Actually Do’: Medtronic Diabetes Execs On Marketing Plans For MiniMed 780G

In this third Exec Chat with leaders at major diabetes companies that presented at ADA’s Scientific Sessions 2023, Medtech Insight interviewed Medtronic diabetes business leaders Ali Dianaty and Jennifer McVean about the company’s marketing strategy for the recently launched MiniMed 780G with meal detection technology, plans for the Simplera disposable CGM, outlook on the consumer market, and more.  

Medtronic MiniMed 780G Data Shows Simplified Meal Management Helps Users With Glycemic Target

Medtronic announced data at the ADA conference today showing the MiniMed 780G advanced hybrid close loop system’s meal detection technology helps reduce time spent in hyperglycemia.

News We're Watching: Renal Denervation Trial Highlights, TAP Pilot Update, Cardiohelp Safety Alert

Two new studies support ReCor’s Radiance Ultrasound Renal Denervation System, and renal denervation also won the backing of European medical societies. Additionally, the FDA issued an update on the Total Product Life Cycle Advisory Program (TAP) “soft” pilot, and a disposable component of the Getinge/Maquet Cardiohelp system was flagged for possible sterility issues.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT147702

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel